Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.

IF 3.8 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current opinion in lipidology Pub Date : 2023-08-01 DOI:10.1097/MOL.0000000000000877

Salvatore Giordano, Alberto Polimeni, Giovanni Esposito, Ciro Indolfi, Carmen Spaccarotella

{"title":"Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.","authors":"Salvatore Giordano, Alberto Polimeni, Giovanni Esposito, Ciro Indolfi, Carmen Spaccarotella","doi":"10.1097/MOL.0000000000000877","DOIUrl":null,"url":null,"abstract":"Purpose of review: To highlight critical aspects of inclisiran, from preclinical studies to current recommendations in clinical practice and future perspectives.Recent findings: Inclisiran use has been recently approved by regulatory agencies. The evidence of its efficacy and safety makes it a promising therapeutical tool for treating dyslipidemias.Summary: The link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well established. Inclisiran, a small interfering RNA, has proven its safety and efficacy in reducing LDL-cholesterol, and FDA and EMA have recently approved its use. This review illustrates the development, structure, and mechanism of action of inclisiran and provides information regarding its efficacy, safety, and current recommendation in clinical practice. Moreover, it provides key information on the most recent/ongoing trials that will help us to implement the use of inclisiran in clinical practice.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":"34 4","pages":"133-140"},"PeriodicalIF":3.8000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000000877","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: To highlight critical aspects of inclisiran, from preclinical studies to current recommendations in clinical practice and future perspectives.

Recent findings: Inclisiran use has been recently approved by regulatory agencies. The evidence of its efficacy and safety makes it a promising therapeutical tool for treating dyslipidemias.

Summary: The link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well established. Inclisiran, a small interfering RNA, has proven its safety and efficacy in reducing LDL-cholesterol, and FDA and EMA have recently approved its use. This review illustrates the development, structure, and mechanism of action of inclisiran and provides information regarding its efficacy, safety, and current recommendation in clinical practice. Moreover, it provides key information on the most recent/ongoing trials that will help us to implement the use of inclisiran in clinical practice.

查看原文本刊更多论文

Inclisiran:一种新型有效的低密度脂蛋白降胆固醇剂的现状和未来展望。

综述的目的:强调inclisiran的关键方面，从临床前研究到临床实践中的当前建议和未来前景。最近的发现:监管机构最近批准了Inclisiran的使用。其有效性和安全性的证据使其成为治疗血脂异常的有前途的治疗工具。总结:低密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病(ASCVD)之间的联系已得到充分证实。Inclisiran是一种小干扰RNA，已经证明其在降低低密度脂蛋白胆固醇方面的安全性和有效性，FDA和EMA最近批准了它的使用。这篇综述阐述了inclisiran的发展、结构和作用机制，并提供了有关其疗效、安全性和目前在临床实践中的推荐信息。此外，它提供了最新/正在进行的试验的关键信息，这将有助于我们在临床实践中实施inclisiran的使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in lipidology 医学-内分泌学与代谢

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.